Coming soon. Phase I of this new 50-acre site includes 2 API manufacturing plants for small molecule drug, 1 large-scale manufacturing plant for oligonucleotides, peptides, and related synthetic conjugates. The 1st plant is expected to start operation in 2027.
In the future, the site will add at least 4 more plants, supporting small molecule, oligonucleotide and peptide manufacturing.
